How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease

British Journal of Haematology

Volumn 170, Issue 6, 2015, Pages 745-756

  Gardner, Kate ^a,b   Hoppe, Carolyn ^c   Mijovic, Aleksandar ^b   Thein, Swee L ^a,b,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c CHILDREN S HOSPITAL OAKLAND   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Alloantibodies; Delayed haemolytic transfusion reactions; Hyperhaemolysis; Sickle cell disease; Vaso occlusive crisis

Indexed keywords

ALLOANTIBODY; ANTIANEMIC AGENT; AUTOANTIBODY; CORTICOSTEROID; ERYTHROPOIETIN; HEMOGLOBIN A; HEMOGLOBIN S; HLA ANTIBODY; IMMUNOGLOBULIN; IRON; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; RITUXIMAB;

ALLOIMMUNIZATION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN MATCHING; APHERESIS; BLOOD GROUP TYPING; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; BYSTANDER HEMOLYSIS; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COOMBS TEST; DELAYED HEMOLYTIC TRANSFUSION REACTION; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; ETHNIC DIFFERENCE; GENOTYPE; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; MEDICAL HISTORY; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT SELECTION; PERIOPERATIVE TRANSFUSION; PHYSICAL EXAMINATION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEROLOGY; SICKLE CELL ANEMIA; SUPPORTIVE CARE; VASCULAR DISEASE; VASOOCCLUSIVE CRISIS; ADOLESCENT; ADVERSE EFFECTS; ANEMIA, SICKLE CELL; CASE REPORT; COMPLICATION; DISEASE MANAGEMENT; FEMALE; MALE; MIDDLE AGED; TRANSFUSION REACTION;

ADOLESCENT; ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TRANSFUSION REACTION;

EID: 84940587614     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13494     Document Type: Review

References (72)

1. Adams, R.J., McKie, V.C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F.T., Bonds, D.R. & Brambilla, D. (1998) Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New England Journal of Medicine, 339, 5-11.
2. Aygun, B., Padmanabhan, S., Paley, C. & Chandrasekaran, V. (2002) Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion, 42, 37-43.
3. Bachmeyer, C., Maury, J., Parrot, A., Bachir, D., Stankovic, K., Girot, R. & Lionnet, F. (2010) Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. American Journal of Hematology, 85, 91-92.
4. Bauer, M.P., Wiersum-Osselton, J., Schipperus, M., Vandenbroucke, J.P. & Briet, E. (2007) Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion, 47, 2066-2071.
5. Beard, M.J., Cardigan, R., Seghatchian, J., Krailadsiri, P. & Williamson, L.M. (2004) Variables determining blockage of WBC-depleting filters by Hb sickle cell trait donations. Transfusion, 44, 422-430.
6. Castellino, S.M., Combs, M.R., Zimmerman, S.A., Issitt, P.D. & Ware, R.E. (1999) Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. British Journal of Haematology, 104, 189-194.
7. Castro, O., Sandler, S.G., Houston-Yu, P. & Rana, S. (2002) Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion, 42, 684-690.
8. Chadebech, P., Habibi, A., Nzouakou, R., Bachir, D., Meunier-Costes, N., Bonin, P., Rodet, M., Chami, B., Galacteros, F., Bierling, P. & Noizat-Pirenne, F. (2009) Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion, 49, 1785-1792.
9. Chou, S.T., Jackson, T., Vege, S., Smith-Whitley, K., Friedman, D.F. & Westhoff, C.M. (2013) High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood, 122, 1062-1071.
10. Cullis, J.O., Win, N., Dudley, J.M. & Kaye, T. (1995) Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Vox Sanguinis, 69, 355-357.
11. Darbari, D.S., Castro, O., Taylor, J.G.T., Fasano, R., Rehm, J., Gordeuk, V.R. & Minniti, C.P. (2008) Severe vaso-occlusive episodes associated with use of systemic corticosteroids in patients with sickle cell disease. Journal of the National Medical Association, 100, 948-951.
12. Davey, R.J., Gustafson, M. & Holland, P.V. (1980) Accelerated immune red cell destruction in the absence of serologically detectable alloantibodies. Transfusion, 20, 348-353.
13. de Montalembert, M., Dumont, M.D., Heilbronner, C., Brousse, V., Charrara, O., Pellegrino, B., Piguet, C., Soussan, V. & Noizat-Pirenne, F. (2011) Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica, 96, 801-807.
14. DeBaun, M.R., Gordon, M., McKinstry, R.C., Noetzel, M.J., White, D.A., Sarnaik, S.A., Meier, E.R., Howard, T.H., Majumdar, S., Inusa, B.P., Telfer, P.T., Kirby-Allen, M., McCavit, T.L., Kamdem, A., Airewele, G., Woods, G.M., Berman, B., Panepinto, J.A., Fuh, B.R., Kwiatkowski, J.L., King, A.A., Fixler, J.M., Rhodes, M.M., Thompson, A.A., Heiny, M.E., Redding-Lallinger, R.C., Kirkham, F.J., Dixon, N., Gonzalez, C.E., Kalinyak, K.A., Quinn, C.T., Strouse, J.J., Miller, J.P., Lehmann, H., Kraut, M.A., Ball, W.S. Jr, Hirtz, D. & Casella, J.F. (2014) Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. New England Journal of Medicine, 371, 699-710.
15. Delmonte, L., Cantini, M., Olivieri, O. & De Franceschi, L. (2013) Immunoglobulin-resistant delayed hemolytic transfusion reaction treated with rituximab in an adult sickle cell patient. Transfusion, 53, 688-689.
16. Diamond, W.J., Brown, F.L. Jr, Bitterman, P., Klein, H.G., Davey, R.J. & Winslow, R.M. (1980) Delayed hemolytic transfusion reaction presenting as sickle-cell crisis. Annals of Internal Medicine, 93, 231-234.
17. Drasar, E., Igbineweka, N., Vasavda, N., Free, M., Awogbade, M., Allman, M., Mijovic, A. & Thein, S.L. (2011) Blood transfusion usage among adults with sickle cell disease - a single institution experience over ten years. British Journal of Haematology, 152, 766-770.
18. El-Husseini, A. & Sabry, A. (2010) Fatal hyperhemolytic delayed transfusion reaction in sickle cell disease: a case report and literature review. American Journal of Emergency Medicine, 28, e1065-e1068.
19. Elenga, N., Mialou, V., Kebaili, K., Galambrun, C., Bertrand, Y. & Pondarre, C. (2008) Severe neurologic complication after delayed hemolytic transfusion reaction in 2 children with sickle cell anemia: significant diagnosis and therapeutic challenges. Journal of Pediatric Hematology/Oncology, 30, 928-930.
20. Fasano, R.M., Booth, G.S., Miles, M., Du, L., Koyama, T., Meier, E.R. & Luban, N.L. (2015) Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. British Journal of Haematology, 168, 291-300.
21. Garratty, G. (1997) Severe reactions associated with transfusion of patients with sickle cell disease. Transfusion, 37, 357-361.
22. Garratty, G. (2004) Autoantibodies induced by blood transfusion. Transfusion, 44, 5-9.
23. Harm, S.K., Yazer, M.H., Monis, G.F., Triulzi, D.J., Aubuchon, J.P. & Delaney, M. (2014) A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease. American Journal of Clinical Pathology, 141, 256-261.
24. Heddle, N.M., Soutar, R.L., Ohoski, P.L., Singer, J., Mcbride, J.A., Ali, M.A.M. & Kelton, J.G. (1995) A prospective-study to determine the frequency and clinical-significance of alloimmunization posttransfusion. British Journal of Haematology, 91, 1000-1005.
25. Heisto, H., Myhre, K., Vogt, E. & Heier, A.M. (1960) Haemolytic transfusion reaction due to incompatibility without demonstrable antibodies. Vox Sanguinis, 5, 538-544.
26. Howard, J., Malfroy, M., Llewelyn, C., Choo, L., Hodge, R., Johnson, T., Purohit, S., Rees, D.C., Tillyer, L., Walker, I., Fijnvandraat, K., Kirby-Allen, M., Spackman, E., Davies, S.C. & Williamson, L.M. (2013) The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet, 381, 930-938.
27. Kalyanaraman, M., Heidemann, S.M., Sarnaik, A.P., Meert, K.L. & Sarnaik, S.A. (1999) Anti-s antibody-associated delayed hemolytic transfusion reaction in patients with sickle cell anemia. Journal of Pediatric Hematology/oncology, 21, 70-73.
28. King, K.E., Shirey, R.S., Lankiewicz, M.W., Young-Ramsaran, J. & Ness, P.M. (1997) Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells. Transfusion, 37, 376-381.
29. Lasalle-Williams, M., Nuss, R., Le, T., Cole, L., Hassell, K., Murphy, J.R. & Ambruso, D.R. (2011) Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion, 51, 1732-1739.
30. Little, J.A., McGowan, V.R., Kato, G.J., Partovi, K.S., Feld, J.J., Maric, I., Martyr, S., Taylor, J.G.t., Machado, R.F., Heller, T., Castro, O. & Gladwin, M.T. (2006) Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica, 91, 1076-1083.
31. McGlennan, A.P. & Grundy, E.M. (2005) Delayed haemolytic transfusion reaction and hyperhaemolysis complicating peri-operative blood transfusion in sickle cell disease. Anaesthesia, 60, 609-612.
32. Mijovic, A., Perera, I.G. & Thein, S.L. (2013) Red blood cell alloimmunization in sickle cell disease-prevalence and trends: a single-center cross-sectional study from United Kingdom. Transfusion, 53, 3279-3280.
33. Milkins, C., Berryman, J., Cantwell, C., Elliott, C., Haggas, R., Jones, J., Rowley, M., Williams, M. & Win, N. (2013) Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. British Committee for Standards in Haematology. Transfusion Medicine (Oxford, England), 23, 3-35.
34. Nagel, R.L., Vichinsky, E., Shah, M., Johnson, R., Spadacino, E., Fabry, M.E., Mangahas, L., Abel, R. & Stamatoyannopoulos, G. (1993) F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study. Blood, 81, 9-14.
35. National Institutes of Health: National Heart Lung and Blood Institute (2014) Evidence-based management of sickle cell disease. Buchanan, GR and Yawn BP. http://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/sickle-cell-disease-report.pdf
36. Natukunda, B., Schonewille, H., van de Watering, L. & Brand, A. (2010) Prevalence and specificities of red blood cell alloantibodies in transfused Ugandans with different diseases. Vox Sanguinis, 98, 167-171.
37. Noizat-Pirenne, F., Bachir, D., Chadebech, P., Michel, M., Plonquet, A., Lecron, J.C., Galacteros, F. & Bierling, P. (2007) Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica, 92, e132-e135.
38. Noizat-Pirenne, F., Habibi, A., Mekontso-Dessap, A., Razazi, K., Chadebech, P., Mahevas, M., Vingert, B., Bierling, P., Galacteros, F., Bartolucci, P. & Michel, M. (2015) The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease. Vox Sanguinis, 108, 262-267.
39. O'Suoji, C., Liem, R.I., Mack, A.K., Kingsberry, P., Ramsey, G. & Thompson, A.A. (2013) Alloimmunization in sickle cell anemia in the era of extended red cell typing. Pediatric Blood & Cancer, 60, 1487-1491.
40. Olujohungbe, A., Hambleton, I., Stephens, L., Serjeant, B. & Serjeant, G. (2001) Red cell antibodies in patients with homozygous sickle cell disease: a comparison of patients in Jamaica and the United Kingdom. British Journal of Haematology, 113, 661-665.
41. Petz, L.D. (2006) Bystander immune cytolysis. Transfusion Medicine Reviews, 20, 110-140.
42. Petz, L.D. & Garratty, G. (2004a) Hemolytic transfusion reactions. In: Immune Hemolytic Anemias, 2nd edn pp. 541-572. Churchill Livingstone, Philadelphia.
43. Petz, L.D. & Garratty, G. (2004b) Bystander immune haemolysis. In: Immune Hemolytic Anemias, 2nd edn, pp. 358-364. Churchill Livingstone, Philadelphia.
44. Petz, L.D., Calhoun, L., Shulman, I.A., Johnson, C. & Herron, R.M. (1997) The sickle cell hemolytic transfusion reaction syndrome. Transfusion, 37, 382-392.
45. Reisner, E.G., Kostyu, D.D., Phillips, G., Walker, C. & Dawson, D.V. (1987) Alloantibody responses in multiply transfused sickle cell patients. Tissue Antigens, 30, 161-166.
46. Roger, S.D., Macdougall, I.C., Thuraisingham, R.C. & Raine, A.E. (1991) Erythropoietin in anemia of renal failure in sickle cell disease. New England Journal of Medicine, 325, 1175-1176.
47. Rosse, W.F., Gallagher, D., Kinney, T.R., Castro, O., Dosik, H., Moohr, J., Wang, W. & Levy, P.S. (1990) Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood, 76, 1431-1437.
48. Scheunemann, L.P. & Ataga, K.I. (2010) Delayed hemolytic transfusion reaction in sickle cell disease. American Journal of the Medical Sciences, 339, 266-269.
49. Schonewille, H., van de Watering, L.M., Loomans, D.S. & Brand, A. (2006) Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion, 46, 250-256.
50. Sherwood, J.B., Goldwasser, E., Chilcote, R., Carmichael, L.D. & Nagel, R.L. (1986) Sickle cell anemia patients have low erythropoeitin levels for their degree of anemia. Blood, 67, 46-49.
51. Silvy, M., Tournamille, C., Babinet, J., Pakdaman, S., Cohen, S., Chiaroni, J., Galacteros, F., Bierling, P., Bailly, P. & Noizat-Pirenne, F. (2014) Red blood cell immunization in sickle cell disease: evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica, 99, e115-e117.
52. Sosler, S.D., Jilly, B.J., Saporito, C. & Koshy, M. (1993) A simple, practical model for reducing alloimmunization in patients with sickle cell disease. American Journal of Hematology, 43, 103-106.
53. Steinberg, M.H. (1991) Erythropoietin for anemia of renal failure in sickle cell disease. New England Journal of Medicine, 324, 1369-1370.
54. Steinberg, M.H. (2014) More blood for sickle cell anemia. New England Journal of Medicine, 371, 775-776.
55. Stewart, J.W. & Mollison, P.L. (1959) Rapid destruction of apparently compatible red cells. British Medical Journal, 1, 1274-1275.
56. Stowell, S.R., Winkler, A.M., Maier, C.L., Arthur, C.M., Smith, N.H., Girard-Pierce, K.R., Cummings, R.D., Zimring, J.C. & Hendrickson, J.E. (2012) Initiation and regulation of complement during hemolytic transfusion reactions. Clinical & Developmental Immunology, 2012, 307093.
57. Talano, J.A., Hillery, C.A., Gottschall, J.L., Baylerian, D.M. & Scott, J.P. (2003) Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics, 111, e661-e665.
58. Tomson, C.R.V., Edmunds, M.E., Chambers, K., Bricknell, S., Feehally, J. & Walls, J. (1992) Effect of recombinant human erythropoietin on erythopoiesis in homozygous sickle-cell anaemia and renal failure. Nephrology, Dialysis, Transplantation, 7, 817-821.
59. Uhlmann, E.J., Shenoy, S. & Goodnough, L.T. (2014) Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion. Transfusion, 54, 384-388.
60. van der Hart, M., Engelfriet, C.P., Prins, H.K. & van Loghem, J.J. (1963) A haemolytic transfusion reaction without demonstrable antibodies in vitro. Vox Sanguinis, 8, 363-370.
61. Vichinsky, E.P., Earles, A., Johnson, R.A., Hoag, M.S., Williams, A. & Lubin, B. (1990) Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. New England Journal of Medicine, 322, 1617-1621.
62. Vichinsky, E.P., Haberkern, C.M., Neumayr, L., Earles, A.N., Black, D., Koshy, M., Pegelow, C., Abboud, M., Ohene-Frempong, K. & Iyer, R.V. (1995) A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. New England Journal of Medicine, 333, 206-213.
63. Vichinsky, E.P., Luban, N.L., Wright, E., Olivieri, N., Driscoll, C., Pegelow, C.H. & Adams, R.J. (2001) Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion, 41, 1086-1092.
64. Vidler, J.B., Gardner, K., Amenyah, K., Mijovic, A. & Thein, S.L. (2015) Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. British Journal of Haematology, DOI: 10.1111/bjh.13339.
65. Wahl, S.K., Garcia, A., Hagar, W., Gildengorin, G., Quirolo, K. & Vichinsky, E. (2012) Lower alloimmunization rates in pediatric sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions. Transfusion, 52, 2671-2676.
66. Wayne, A.S., Kevy, S.V. & Nathan, D.G. (1993) Transfusion management of sickle cell disease. Blood, 81, 1109-1123.
67. Win, N., Doughty, H., Telfer, P., Wild, B.J. & Pearson, T.C. (2001) Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion, 41, 323-328.
68. Win, N., Sinha, S., Lee, E. & Mills, W. (2010) Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review. Transfusion Medicine Reviews, 24, 64-67.
69. Yazdanbakhsh, K., Ware, R.E. & Noizat-Pirenne, F. (2012) Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood, 120, 528-537.
70. Yazer, M.H., Triulzi, D.J., Shaz, B., Kraus, T. & Zimring, J.C. (2009) Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization? Transfusion, 49, 1070-1075.
71. Young, P.P., Uzieblo, A., Trulock, E., Lublin, D.M. & Goodnough, L.T. (2004) Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia? Transfusion, 44, 67-72.
72. Zimring, J.C., Spitalnik, S.L., Roback, J.D. & Hillyer, C.D. (2007) Transfusion-induced autoantibodies and differential immunogenicity of blood group antigens: a novel hypothesis. Transfusion, 47, 2189-2196.